Actuate Therapeutics' oral elraglusib shows up to 77% tumor growth inhibition in preclinical melanoma study
ACTU•Actuate Therapeutics said preclinical testing found oral elraglusib inhibited melanoma tumor growth by up to 77%, and it plans to begin a Phase 1/2 trial in Q1 2027.
1. Trial planned for 2027
Actuate Therapeutics plans to begin a Phase 1/2 trial of daily oral elraglusib in Q1 2027, initially enrolling patients with refractory metastatic melanoma. Preclinical results presented at ENA 2026 on November 18 showed the drug inhibited melanoma growth on its own, with greater activity at higher exposures, and shifted the tumor immune environment toward greater antitumor activity. Phase 1 safety and drug-exposure data will guide Phase 2 dose selection.




